Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2026)

Cartesian Therapeutics (RNAC) has 9 years of Operating Leases data on file, last reported at $11.9 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $11.9 million, down 15.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 million (down 15.72% YoY), and the FY2025 annual result was $8.5 million, down 23.43% from the prior year.
• Operating Leases climbed to $11.9 million in Q1 2026 per RNAC's latest filing, from $8.5 million in the prior quarter.
• Over five years, Operating Leases peaked at $14.9 million in Q2 2024 and troughed at $3.2 million in Q4 2022.
• A 5-year average of $10.4 million and a median of $10.5 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases sank 62.78% in 2022, then soared 174.66% in 2023.
• A 5-year view of Operating Leases shows it stood at $3.2 million in 2022, then soared by 174.66% to $8.8 million in 2023, then increased by 26.67% to $11.1 million in 2024, then retreated by 23.43% to $8.5 million in 2025, then jumped by 39.06% to $11.9 million in 2026.
• Business Quant data shows RNAC's Operating Leases at $11.9 million in Q1 2026, $8.5 million in Q4 2025, and $12.6 million in Q3 2025.